Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Melani

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Leukemia & Lymphoma|January 11, 2019
Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomasJoseph Roswarski, Mark Roschewski, Christopher Melani, et al.
Leukemia & Lymphoma|June 24, 2017
MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-RCatherine Lai, Mark Roschewski, Christopher Melani, et al.
Blood Advances|August 25, 2021
Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCLMilos D Miljkovic, Christopher Melani, Stefania Pittaluga, et al.
Blood Advances|July 26, 2022
Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairmentCatherine Lai, Diane E Cole, Seth M Steinberg, et al.
Blood Cancer Discovery|September 11, 2020
Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin LymphomaStefania Pittaluga, Alina Nicolae, George W Wright, et al.
Leukemia & Lymphoma|February 3, 2025
Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomasRahul Lakhotia, Christopher Melani, Kieron Dunleavy, et al.
British Journal of Haematology|June 16, 2025
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomasRahul Lakhotia, Christopher Melani, Stefania Pittaluga, et al.
Blood Neoplasia|June 23, 2025
A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignanciesMax J Gordon, Sigrid Dubois, Milos D Miljkovic, et al.
British Journal of Haematology|October 31, 2025
Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphomaMax J Gordon, Rahul Lakhotia, Stefania Pittaluga, et al.
Blood Advances|March 4, 2026
A phase 1 trial of romidepsin, azacitidine, dexamethasone and lenalidomide in relapsed or refractory T-cell lymphomaMax J Gordon, Milos D Miljkovic, Paige Milhon, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|January 11, 2019
Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomasJoseph Roswarski, Mark Roschewski, Christopher Melani, et al.
Leukemia & Lymphoma|June 24, 2017
MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-RCatherine Lai, Mark Roschewski, Christopher Melani, et al.
Blood Advances|August 25, 2021
Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCLMilos D Miljkovic, Christopher Melani, Stefania Pittaluga, et al.
Blood Advances|July 26, 2022
Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairmentCatherine Lai, Diane E Cole, Seth M Steinberg, et al.
Blood Cancer Discovery|September 11, 2020
Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin LymphomaStefania Pittaluga, Alina Nicolae, George W Wright, et al.
Leukemia & Lymphoma|February 3, 2025
Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomasRahul Lakhotia, Christopher Melani, Kieron Dunleavy, et al.
British Journal of Haematology|June 16, 2025
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomasRahul Lakhotia, Christopher Melani, Stefania Pittaluga, et al.
Blood Neoplasia|June 23, 2025
A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignanciesMax J Gordon, Sigrid Dubois, Milos D Miljkovic, et al.
British Journal of Haematology|October 31, 2025
Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphomaMax J Gordon, Rahul Lakhotia, Stefania Pittaluga, et al.
Blood Advances|March 4, 2026
A phase 1 trial of romidepsin, azacitidine, dexamethasone and lenalidomide in relapsed or refractory T-cell lymphomaMax J Gordon, Milos D Miljkovic, Paige Milhon, et al.
Pageof 3